Pharmacy & Therapeutics Society: PANEL DISCUSSION
In: Health
18 May 2010The P&T Society’s Response to the Institute of Medicine’s Reports
Moderator: Joseph Eichenholz, Managing Director, Tri-genesis Management Systems, Chatham, New Jersey. (See Mr. Eichenholz’ overview on page 439.)
Speaker: Michael B. Nichol, PhD, Associate Professor and Chair, Department of Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, Los Angeles, California
Pharmacy & Therapeutics Society: KEYNOTE ADDRESS
In: Health
17 May 2010The Institute of Medicine’s Agenda for Health Care Quality: Past, Present, and Future
Keynote Speaker: Harvey V. Fineberg, MD, PhD, President, Institute of Medicine.
The pathways to improving the quality of health care in the U.S. involve two strategies: developing better drug interventions and devising better ways to do things using existing technologies.
Pharmacy & Therapeutics Society
In: Health
16 May 2010
PRESIDENT’S ADDRESS
The Value of Therapy: The Role of the P&T Society
Speaker: J. Lyle Bootman, PhD, President, P&T Society.
Drug-related morbidity and mortality represent a “silent disease in America.” The value of the quality of health care depends on the accessibility of medicine to patients and on the cost of medicine. The Institute of Medicine (IOM) is attempting to identify some of the reasons for the health care crisis in the U.S. and to challenge the health care community to eliminate the barriers to quality of care.
American Urological Association: Extended-Release Muscarinic Agonist (Tolterodine) for Overactive Bladder
In: Disease
14 May 2010
Speaker: Jay M. Young, MD, Medical Director, South Orange County Medical Research Center, Laguna Woods, California.
Patients with overactive bladder who received extended-release (ER) tolterodine tartrate (Detrol drug LA, Pharmacia) experienced significantly improved perceptions of urinary urgency and bladder condition, compared with patients who took placebo.
American Urological Association: Vardenafil for Erectile Dysfunction Irrespective of Prior Sildenafil Use
In: Disease
13 May 2010Speaker: William G. Moseley, MD, Medical Director, San Diego Uro-Research, San Diego, California.
Vardenafil (Levitra drug, Bayer/GlaxoSmithKline), a new anti-impotence agent, provided clinically significant, sustained improvement in erectile function over a two-year period in men with erectile dysfunction (ED), whether or not they had previously used the original anti-impotence drug sildenafil (Viagra®, Pfizer).
American Urological Association: Alprostadil Urethral Suppository for Erectile Dysfunction After Radical Prostatectomy
In: Disease
12 May 2010Speaker: Craig Zippe, MD, Staff Surgeon, Section of Urologic Oncology, and Co-Director, Prostate Center and Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, The Cleveland Clinic, Cleveland, Ohio.
The early use of an alprostadil urethral suppository (Muse®, Vivus, Inc.) in men following bilateral nerve-sparing radical prostatectomy appears to facilitate a rapid return to and a high rate of early recovery of normal sexual function.
American Urological Association
In: Disease
11 May 2010
Long-Acting LH-RH Agonist Depot (Leuprolide Acetate) for Prostate Cancer
Speaker: Robert C. Tyler, MD, Director of Clinical Research, Atrix Laboratories, Inc., Fort Collins, Colorado.
A new six-month subcutaneous (SC) depot of leuprolide acetate (Eligard®, Atrix Laboratories, Inc.), a synthetic luteinizing hormone-releasing hormone (LH-RH) agonist, consistently produced and maintained safe and effective serum testosterone suppression. Total serum testosterone concentrations were well below the medical castrate level of less than 50 ng/dl in adult men with prostate cancer.
About this blog
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.
Photostream
Categories
- Anesthesia (109)
- Dental treatment (46)
- Disease (12)
- Drug (15)
- Health (49)
- Main (71)
- Shelby Miller: Hi, i'm doing a project called History day. The theme is innovation in history and I choose Anesthes [...]
- Tim Tav: For newly qualified dentists it may help to join firms with a training department that may help to s [...]
- Prierien: Great. Now I can say thank you! [...]
- Mark: I bookmarked this link. Thank you for good job! [...]
- Robor: Hi, Thank you! I would now go on this blog every day! Robor [...]
- FARS and FFIRS
- Meals at Medical Meetings: Mixed Messages
- Evidence-Based Herbal Medicine
- The American College of Cardiology: Beta Blockade in Severe Heart Failure and Extremely Depressed LVEF
- The American College of Cardiology: Antiplatelet Therapy for In-Stent Restenosis Post-Brachytherapy
- The American College of Cardiology
- A Cost Analysis of Switching Calcium Channel Blockers: DISCUSSION
- A Cost Analysis of Switching Calcium Channel Blockers: RESULTS
- A Cost Analysis of Switching Calcium Channel Blockers: Study Design
- A Cost Analysis of Switching Calcium Channel Blockers